Belite Bio Inc BLTE.OQ BLTE.O is expected to show no change in quarterly revenue when it reports results on March 2 for the period ending December 31 2025
LSEG's mean analyst estimate for Belite Bio Inc is for a loss of 55 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Belite Bio Inc is $193.00, about 2.4% above its last closing price of $188.55
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.47 | -0.49 | -0.65 | Missed | -33.3 |
Jun. 30 2025 | -0.47 | -0.42 | -0.50 | Missed | -19.8 |
Mar. 31 2025 | -0.34 | -0.37 | -0.45 | Missed | -20.5 |
Dec. 31 2024 | -0.29 | -0.31 | -0.32 | Missed | -4 |
Sep. 30 2024 | -0.29 | -0.29 | -0.28 | Beat | 2.8 |
Jun. 30 2024 | -0.27 | -0.25 | -0.31 | Missed | -22.7 |
Mar. 31 2024 | -0.31 | -0.28 | -0.27 | Beat | 4.9 |
Dec. 31 2023 | -0.33 | -0.30 | -0.25 | Beat | 16.7 |
This summary was machine generated February 27 at 22:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)